AVLSA
DNTH icon

Atlas Venture Life Science Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-76,979
Closed -$2.11M – 14
2024
Q3 		$2.11M Sell
76,979
-60,000
-44% -$1.67M 0.2% 13
2024
Q2 		$3.55M Sell
136,979
-50,000
-27% -$1.2M 0.37% 13
2024
Q1 		$5.61M Sell
186,979
-50,000
-21% -$1.09M 0.52% 14
2023
Q4 		$2.46M Hold
236,979
– – 0.29% 14
2023
Q3 		$3.24M Sell
236,979
-2
-0% -$25 0.5% 14
2023
Q2 		$2.87M Hold
236,981
– – 0.36% 14
2023
Q1 		$3.01M Buy
236,981
+19,697
+9% +$218K 0.41% 14
2022
Q4 		$1.37M Hold
217,284
– – 0.17% 17
2022
Q3 		$4.9M Hold
217,284
– – 0.54% 13
2022
Q2 		$4.17M Hold
217,284
– – 0.7% 12
2022
Q1 		$10.1M Hold
217,284
– – 1.27% 11
2021
Q4 		$15.4M Buy
+217,284
New +$21.8M 1.41% 12

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atlas Venture Life Science Advisors's DNTH Position: Q4 2024 in Review

Atlas Venture Life Science Advisors sold out of Dianthus Therapeutics (DNTH) in Q4 2024, closing a stake of 76,979 shares — an estimated $2.11M sold.

Atlas Venture Life Science Advisors first reported a position in DNTH in Q4 2021 and held it in 12 quarters. The position peaked at $15.4M in Q4 2021. 95 funds tracked by Wall St. Rank hold DNTH as of Q4 2024.

  • Atlas Venture Life Science Advisors reported no remaining Dianthus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 76,979 Dianthus Therapeutics shares in Q4 2024, an estimated $2.11M.
  • Atlas Venture Life Science Advisors first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 12 quarters.
  • Atlas Venture Life Science Advisors's Dianthus Therapeutics position peaked at $15.4M in Q4 2021.
  • 95 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2024.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.